<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01684800</url>
  </required_header>
  <id_info>
    <org_study_id>000029</org_study_id>
    <nct_id>NCT01684800</nct_id>
  </id_info>
  <brief_title>Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Women</brief_title>
  <acronym>NOC</acronym>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Trial Investigating the Efficacy and Safety of Two Different Dose Levels of Desmopressin for the Treatment of Nocturia in Adult Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the efficacy and safety of two different dose
      levels of desmopressin orally disintegrating tablets against placebo for the treatment of
      nocturia in adult women during 12 weeks treatment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean number of nocturnal voids</measure>
    <time_frame>During 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean time to first void</measure>
    <time_frame>During 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder status (33% reduction in nocturnal voids)</measure>
    <time_frame>During 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean number of nocturnal voids</measure>
    <time_frame>1, 4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean time to first void</measure>
    <time_frame>1, 4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder status (33% reduction in nocturnal voids)</measure>
    <time_frame>1, 4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean nocturnal urine volume</measure>
    <time_frame>1, 4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in nocturnal polyuria index</measure>
    <time_frame>1, 4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the effect on sleep disturbance</measure>
    <time_frame>1, 4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the impact on quality of life</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, changes from baseline in serum sodium level, laboratory values</measure>
    <time_frame>During 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">178</enrollment>
  <condition>Nocturia</condition>
  <arm_group>
    <arm_group_label>A. Desmopressin 10 microgram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B. Desmopressin 25 microgram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C. Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A. Desmopressin 10 microgram</intervention_name>
    <description>1 orally disintegrating tablet every night during study period</description>
    <arm_group_label>A. Desmopressin 10 microgram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B: Desmopressin 25 microgram</intervention_name>
    <description>1 orally disintegrating tablet every night during study period</description>
    <arm_group_label>B. Desmopressin 25 microgram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C: Placebo</intervention_name>
    <description>1 orally disintegrating tablet every night during study period</description>
    <arm_group_label>C. Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has given written consent prior to any trial-related activity is performed.

          -  Female sex, aged 20 years or older.

          -  At least 2 nocturnal voids every night in a consecutive 3-day period as documented in
             the diary during the screening period.

          -  Has given agreement about contraception during the trial.

        Exclusion Criteria:

          -  Showing symptoms of any of the following diseases: Interstitial cystitis; Overactive
             bladder, defined as &gt;6 daytime voids,≥1 urgency episode and ≥1 urge urinary
             incontinence episode per 24 hours as documented in the 3-day diary period; Severe
             stress urinary incontinence.

          -  Psychogenic or habitual polydipsia.

          -  Urinary retention or a post void residual volume in excess of 150 mL as confirmed by
             bladder ultrasound performed after suspicion of urinary retention.

          -  Cancer.

          -  A history of urologic malignancies or a history of cancer which has not been in
             remission for the last 5 years.

          -  Genito-urinary tract pathology.

          -  Neurogenic detrusor activity.

          -  Suspicion or evidence of heart failure.

          -  Uncontrolled hypertension.

          -  Uncontrolled diabetes mellitus.

          -  Hepatobiliary diseases: Aspartate aminotransferase &gt;80 U/L or alanine aminotransferase
             &gt;90 U/L; Total bilirubin &gt;1.5 mg/dL.

          -  Renal insufficiency: Serum creatinine level &gt;0.82 mg/dL; Estimated glomerular
             filtration rate &lt;50 mL/min.

          -  Hyponatraemia: Serum sodium level &lt;135 mEq/L.

          -  Central or nephrogenic diabetes insipidus.

          -  Syndrome of inappropriate antidiuretic hormone.

          -  Obstructive sleep apnea.

          -  Previous desmopressin treatment.

          -  Treatment with another investigational product within the past 3 months.

          -  Concomitant treatment with any prohibited medication.

          -  Pregnancy, breastfeeding, or a plan to become pregnant during the period of the
             clinical trial.

          -  Alcohol or substance abuse.

          -  A job or lifestyle that may interfere with regular night-time sleep.

          -  A mental condition, lack of decision-making ability, dementia, a speech handicap, or
             any other reason which, in the judgement of the investigator (sub-investigator), would
             impair the participation in the trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferríng Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Japanese Red Cross Nagoya Daiichi Hospital</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic Tsudanuma</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Fukui Hospital</name>
      <address>
        <city>Fukui</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kato Clinic</name>
      <address>
        <city>Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umeyama Clinic</name>
      <address>
        <city>Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harada Urology Clinic</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakaguchi Urological Clinic</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakamura Urology Clinic</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nishi-Yokohama International Hospital</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Shinmidori General Hospital</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Izumino Hospital, Bouchikai</name>
      <address>
        <city>Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kamei Clinic</name>
      <address>
        <city>Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Den Urology Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwasa Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanno Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morimoto Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naka Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uemura Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology department Kuroda Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamaguchi Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamanaka Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuda Clinic</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yasuda Urology Clinic</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirano Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirata Internal Medicine Urology Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J Tower Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koganeibashi Sakura Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kunitachi Sakura Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kusunoki Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moriguchi Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakanoma Clinic Urology Department</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ogawa Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ogikubo Ekimae Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shibuya Shin-minamiguchi Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Kamata Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toru Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2012</study_first_submitted>
  <study_first_submitted_qc>September 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2012</study_first_posted>
  <last_update_submitted>August 22, 2013</last_update_submitted>
  <last_update_submitted_qc>August 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nocturia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

